Aescap Life Sciences & Aescap Genetics

With a portfolio manager that has over 30 years of experience investing in the biotech / life sciences market, Aescap provides investors the chance to invest into the future winners of this industry. An investment in each of the funds will not only allow for a good return on investment, it also enables the development of better treatments for diseases with a high unmet medical need such as ALS, Alzheimer’s, Arthritis, Cancer, MS, Obesity, Parkinson’s and many others. Read more about our two funds below.

Aescap Life Sciences

This fund has a focused portfolio, investing in a variety of around 20 – 25 companies that exploit numerous different medical technologies. In order to reduce the risks of investing in this sector, the fund diversifies its portfolio over many disease areas, different phases of company development and geographical areas. The fund invests mainly in Europe and the US.

Read more about our strategy here.

The fund’s objective is to make an average minimum Annual Net Return (after deduction of costs) of 20% over the mid-term (4-5 years). For wealth managers there is no minimum subscription amount,, though the minimum subscription per time is EUR 10.000. For private individuals the minimum subscription amount is EUR 500.000 with an exception for family and friends for who a minimum of EUR 101.000 applies. Investors can enter and exit the fund twice a month.

ISIN Code Aescap Life Sciences: NL0012343958

Bloomberg: AESCAPI NA Equity

Aescap Genetics

In January 2022, six years after the launch of Aescap Life Sciences, our second fund called Aescap Genetics was launched. The Genetics fund invests exclusively in the fast-growing market of RNA, gene and cell therapy medicines. The advantage of Genetics medicines is their ability to treat diseases at their root cause. They are not only able to treat diseases better but can also treat diseases for which no medicines are available today.

Around 125 public companies have so far launched 50 Genetics medicine and almost 900 others are being tested in humans, and these numbers are growing rapidly.  

Aescap has invested in public Genetics companies since 2016 and the Aescap Genetics fund invests in approximately 15-20 companies. These  companies each have the capacity to minimally double in value over 4-5 years.

The fund has a weekly liquidity with a 5-day notice period. The minimum investment amount for the Aescap Genetics fund is EUR 100.000,-. For wealth managers the minimum subscription amount is EUR 10.000,-.

ISIN Code Aescap Genetics: NL0015000PS9

Bloomberg: AESCGEI NA Equity